X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (496) 496
Publication (48) 48
Newsletter (15) 15
Book Review (9) 9
Book Chapter (3) 3
Dissertation (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (339) 339
mucopolysaccharidosis (245) 245
index medicus (225) 225
female (187) 187
male (183) 183
animals (155) 155
enzyme replacement therapy (127) 127
enzymes (125) 125
child (123) 123
genetics & heredity (111) 111
mucopolysaccharidosis vi - pathology (105) 105
child, preschool (96) 96
adolescent (93) 93
disease (88) 88
medicine, research & experimental (88) 88
adult (82) 82
research (78) 78
pediatrics (67) 67
care and treatment (64) 64
glycosaminoglycans (64) 64
medicine (64) 64
disease models, animal (62) 62
cats (61) 61
lysosomal storage diseases (61) 61
children (58) 58
diagnosis (58) 58
maroteaux-lamy syndrome (54) 54
maroteaux-lamy-syndrome (54) 54
mice (54) 54
health aspects (53) 53
pathology (52) 52
bone-marrow-transplantation (51) 51
analysis (50) 50
infant (49) 49
enzyme-replacement therapy (47) 47
gene therapy (45) 45
genetics (43) 43
mucopolysaccharidoses - pathology (42) 42
endocrinology & metabolism (41) 41
mutation (41) 41
young adult (41) 41
biochemistry & molecular biology (39) 39
article (38) 38
mucopolysaccharidoses (37) 37
mucopolysaccharidosis vi - complications (37) 37
glycosaminoglycans - metabolism (36) 36
multidisciplinary sciences (36) 36
research article (36) 36
transplantation (36) 36
genetic aspects (35) 35
patients (35) 35
mouse model (34) 34
mucopolysaccharidosis i - pathology (34) 34
mucopolysaccharidosis vi - diagnosis (33) 33
mucopolysaccharidosis vi - genetics (33) 33
treatment outcome (33) 33
medicine & public health (32) 32
ophthalmology (32) 32
lysosomal storage disease (31) 31
medical research (31) 31
mucopolysaccharidoses - complications (31) 31
animal models (30) 30
fibroblasts (30) 30
hurler-syndrome (30) 30
lysosomal storage disorders (30) 30
n-acetylgalactosamine-4-sulfatase - genetics (30) 30
phenotype (30) 30
radiography (30) 30
n-acetylgalactosamine 4-sulfatase (29) 29
lysosomal storage (28) 28
metabolic disorders (28) 28
mucopolysaccharidosis vi (28) 28
feline model (27) 27
mucopolysaccharidoses - therapy (27) 27
mucopolysaccharidosis type vi (27) 27
review (27) 27
usage (27) 27
congenital, hereditary, and neonatal diseases and abnormalities (26) 26
mucopolysaccharidosis vi - drug therapy (26) 26
brain (25) 25
glycosaminoglycans - urine (25) 25
medicine, experimental (25) 25
mucopolysaccharidosis vi - enzymology (25) 25
mucopolysaccharidosis vi - metabolism (25) 25
physiological aspects (25) 25
recombinant proteins - therapeutic use (25) 25
science (25) 25
dogs (24) 24
mucopolysaccharidosis iv - pathology (24) 24
nutritional and metabolic diseases (24) 24
pharmacology (24) 24
sulfates (24) 24
disorders (23) 23
heparan sulfate (23) 23
model (23) 23
stem cells (23) 23
therapy (23) 23
age (22) 22
alpha-l-iduronidase (22) 22
biology (22) 22
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (475) 475
Italian (24) 24
German (5) 5
Russian (5) 5
Portuguese (4) 4
Chinese (1) 1
Danish (1) 1
French (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 8, p. e22447
Background: Although enzyme replacement therapy (ERT) is available for several lysosomal storage disorders, the benefit of this treatment to the skeletal... 
MECHANISM | GENE | MULTIDISCIPLINARY SCIENCES | ARYLSULFATASE-B | JOINT DISEASE | BONE | IDENTIFICATION | Bone and Bones - pathology | Chondrocytes - pathology | Enzyme Replacement Therapy | Anti-Inflammatory Agents - pharmacology | Humans | Mucopolysaccharidosis VI - pathology | Motor Activity - drug effects | Rats | Trachea - drug effects | Bone and Bones - drug effects | Mucopolysaccharidosis VI - therapy | Trachea - pathology | Cartilage, Articular - pathology | Chondrocytes - drug effects | Gait - drug effects | Animals | Anti-Inflammatory Agents - therapeutic use | Cartilage, Articular - drug effects | Mucopolysaccharidosis VI - physiopathology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Trachea - abnormalities | Enzymes | Medical research | Tumor necrosis factor | Collagen | Medicine, Experimental | Mucopolysaccharidosis | Gene therapy | Health aspects | Biopharmaceutics | Therapy | Animal models | Deformation | Motor activity | Disorders | N-acetyl-galactosamine | Clinical trials | Lysosomal storage diseases | Systematic review | Cartilage | Angiogenesis | Bone growth | Computed tomography | Rodents | Computer architecture | Toll-like receptors | Ceramide | Bones | Bioindicators | TRANCE protein | Trachea | Recombinant | Cytokines | Poly(ADP-ribose) polymerase | Cystic fibrosis | Inflammation | Cartilage (articular) | TLR4 protein | Tumor necrosis factor-α | Crohns disease | Medicine | Serum levels | Rheumatoid arthritis | Chondrocytes | Biomarkers | Skeletal system | Combined treatment | Bone | Apoptosis
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2014, Volume 9, Issue 6, p. e100882
Background: We previously demonstrated the benefits of daily, oral pentosan polysulfate (PPS) treatment in a rat model of mucopolysaccharidosis (MPS) type VI.... 
SYNOVIAL-FLUID | MULTIDISCIPLINARY SCIENCES | DISEASE | HORSES | OSTEOARTHRITIS | IDENTIFICATION | PROTEINS | ENZYME REPLACEMENT THERAPY | JOINT | Growth Plate - pathology | Biological Availability | Male | Tomography, X-Ray Computed | Femur - diagnostic imaging | Spine - drug effects | Dose-Response Relationship, Drug | Pentosan Sulfuric Polyester - pharmacology | Injections, Subcutaneous | Growth Plate - drug effects | Female | Pentosan Sulfuric Polyester - therapeutic use | Mucopolysaccharidosis VI - drug therapy | Mucopolysaccharidosis VI - physiopathology | Movement - drug effects | Drug Administration Schedule | Administration, Oral | Glycosaminoglycans - metabolism | Mucopolysaccharidosis VI - pathology | Rats | Femur - drug effects | Pentosan Sulfuric Polyester - administration & dosage | Cartilage, Articular - pathology | Biomechanical Phenomena | Spine - diagnostic imaging | Animals | Mucopolysaccharidosis VI - metabolism | Cartilage, Articular - drug effects | Pentosan Sulfuric Polyester - pharmacokinetics | Enzymes | Mucopolysaccharidosis | Glycosaminoglycans | Osteoarthritis | Pentosan polysulfate | Pediatrics | Liver | Arthritis | Cartilage | Biomedical materials | Reduction | Rodents | Animal tissues | Dentition | Tumor necrosis factor-TNF | Biocompatibility | Bioindicators | Drug dosages | Urine | Antigens | Abnormalities | Markers | Oral administration | Teeth | Cartilage (articular) | Inflammation | Bioavailability | Injection | Medicine | Side effects | Orthopedics | Bone | Deformation effects | Cost analysis | Cartilage diseases
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54459
Background: Pentosan polysulfate (PPS) is an FDA-approved, oral medication with anti-inflammatory and pro-chondrogenic properties. We have previously shown... 
SODIUM | MECHANISM | MULTIDISCIPLINARY SCIENCES | INVOLVEMENT | JOINT DISEASE | INJURY | PROLIFERATION | BONE | INHIBITOR | Tumor Necrosis Factor-alpha - metabolism | Bone and Bones - pathology | Gene Expression - drug effects | Tumor Necrosis Factor-alpha - genetics | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Bone and Bones - drug effects | Chondrocytes - drug effects | Pentosan Sulfuric Polyester - pharmacology | Chemokine CCL3 - genetics | Bone and Bones - metabolism | Chemokine CCL3 - metabolism | Female | Chemokine CCL5 - metabolism | Mucopolysaccharidosis VI - drug therapy | Chondrocytes - metabolism | Biomarkers - metabolism | ADAMTS5 Protein | Chondrocytes - pathology | Joint Deformities, Acquired - metabolism | Mucopolysaccharidosis VI - pathology | Rats | ADAM Proteins - metabolism | Bone Density - drug effects | Animals | Mucopolysaccharidosis VI - metabolism | Joint Deformities, Acquired - drug therapy | Chemokine CCL5 - genetics | Joint Deformities, Acquired - pathology | ADAM Proteins - genetics | Care and treatment | Usage | Mucopolysaccharidosis | Xylans | Health aspects | Pentosan polysulfate | Drugs | Therapy | Femur | Animal models | Deformation | Transplants & implants | Disease | RANTES | Medical services | Antibodies | Prenatal development | Arthritis | Bone (trabecular) | Tissue inhibitor of metalloproteinase 1 | Eye | Cartilage | Computed tomography | Bioaccumulation | Rodents | Animal tissues | Immunotherapy | Fibroblasts | Degeneration | Bioindicators | Bone (cortical) | Drug dosages | Enzymes | Vertebrae | Markers | Teeth | Inflammation | Tumor necrosis factor-α | Secretions | Gene expression | Spines | Medicine | Biomechanics | Grooming | Orthopedics | Chondrocytes | Palliative care | Bone | Geriatrics
Journal Article
American Journal of Medical Genetics Part A, ISSN 1552-4825, 11/2017, Volume 173, Issue 11, pp. 2954 - 2967
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 12/2016, Volume 17, Issue 12, pp. 2004 - 2004
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/1996, Volume 97, Issue 8, pp. 1864 - 1873
Journal Article
Brain & Development, ISSN 0387-7604, 2013, Volume 36, Issue 7, pp. 585 - 592
Abstract Objective: Mucopolysaccharidosis type VI is a rare autosomal recessive storage disorder, caused by deficiency of arylsulfatase B. Data on neurological... 
Neurology | Middle cranial fossa | Subluxation | Atlantoaxial | Mucopolysaccharidosis type VI | Enzyme-replacement | MANAGEMENT |